Feng J T, Shang S, Beretta L
Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Oncogene. 2006 Jun 26;25(27):3810-7. doi: 10.1038/sj.onc.1209551.
The prognosis for hepatocellular carcinoma (HCC) is poor and has not improved in recent years, largely owing to lack of early diagnosis, frequent recurrence after surgery and resistance to chemotherapy. Proteomics holds the promise of improving our understanding of HCC carcinogenesis and progression as well as of discovering novel diagnostics and therapeutics. Proteomic analyses of HCC cell lines, animal models and serum and tumor tissue from patients with HCC have been performed to date. Proteomic technologies have greatly improved in the past few years as reviewed here. It is anticipated that with the recent development of protein tagging, protein separation methods and mass spectrometry sensitivity, proteomic studies of HCC will allow the identification of diagnostic and prognostic biomarkers as well as therapeutic targets, which could greatly improve the clinical management of HCC patients.
肝细胞癌（HCC）的预后较差，近年来并无改善，这主要归因于缺乏早期诊断、术后频繁复发以及对化疗耐药。蛋白质组学有望增进我们对HCC致癌作用和进展的理解，以及发现新的诊断方法和治疗手段。迄今为止，已对HCC细胞系、动物模型以及HCC患者的血清和肿瘤组织进行了蛋白质组学分析。如本文所述，蛋白质组学技术在过去几年中有了很大改进。预计随着蛋白质标记、蛋白质分离方法和质谱灵敏度的最新发展，HCC的蛋白质组学研究将能够识别诊断和预后生物标志物以及治疗靶点，这可能极大地改善HCC患者的临床管理。
